Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 4/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodofiltic Acid SCHEMBL4422554 | 1.00 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR4ALB | |
| Iodofiltic Acid SCHEMBL289760 | 1.00 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR4ALB | |
| SCHEMBL5033209 | 1.00 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR4ALB | |
| SCHEMBL25954990 | 0.87 | MMP12 (0.45) | S1PR2S1PR1 | |
| SCHEMBL10925462 | 0.87 | MAPT (0.50) | S1PR2S1PR1S1PR3ALBALDH1A1 | |
| SCHEMBL10925065 | 0.87 | MAPT (0.54) | S1PR2S1PR1S1PR3ALB | |
| SCHEMBL5809402 | 0.87 | MAPT (0.54) | S1PR2S1PR1S1PR3ALB | |
| SCHEMBL14016007 | 0.86 | MAPT (0.56) | S1PR2S1PR1ALDH1A1TRPA1OXER1 | |
| SCHEMBL5074784 | 0.86 | MAPT (0.56) | S1PR2S1PR1ALDH1A1TRPA1OXER1 | |
| SCHEMBL23983038 | 0.85 | S1PR2 (0.50) | S1PR2S1PR1S1PR3S1PR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871179-B2 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130052129-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | THE GENERAL HOSPITAL CORPORATION (US) | 2013-02-28 | — | — | US | disclosed |
| US-8309053-B2 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-13 | — | — | US | disclosed |
| US-8268291-B2 | Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid | THE GENERAL HOSPITAL CORPORATION (US) | 2012-09-18 | — | — | US | disclosed |
| US-7494642-B2 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | THE GENERAL HOSPITAL CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080213178-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080213173-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor; endo-vinylic variants of cycloalkyl-substituted heptadecanoic acid for example | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214853-A1 | Labeled cycloalkylidene-containing fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart or tumor | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214851-A1 | Synthesis of labeled fatty acid analogs for use in tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1622602-B1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | GEN HOSPITAL CORP (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | GENERAL HOSPITAL CORPORATION, THE | 2004-12-16 | — | — | US | disclosed |
| EP-1067103-B1 | Process for producing halogenated benzene compound | SUMITOMO CHEMICAL CO (JP) | 2003-03-12 | — | — | EP | disclosed |
| EP-0832654-B1 | Radiation protection agents suitable for use with radiopharmaceuticals comprising reducible active ingredients | NIHON MEDIPHYSICS CO LTD (JP) | 2003-01-15 | — | — | EP | disclosed |
| US-6437103-B1 | RADIOIMAGING AGENTS WHICH EXHIBIT HIGH UPTAKE AND RETENTION IN THE MYOCARDIUM; RADIOLABELED FATTY ACID MOLECULE IS AVAILABLE OR FREE OF BONDING AND THUS RETAINS THE TRANSPORT AND BIOCHEMICAL PROPERTIES | BIOSTREAM INC. | 2002-08-20 | — | — | US | disclosed |
| EP-1173226-A2 | FATTY ACID ANALOGS FOR DIAGNOSIS OF CORONARY ARTERY DISEASE | Biostream, Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6307045-B1 | REACTING AN ORGANOMETALLIC COMPOUND WITH A HALIDE ION UNDER LIGHT IRRADIATION CONDITIONS IN THE PRESENCE OF A SEMICONDUCTOR CATALYST WITH A PHOTOCATALYTIC ACTIVITY. | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-1067103-A2 | Process for producing halogenated benzene compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000061196-A2 | FATTY ACID ANALOGS FOR DIAGNOSIS OF CORONARY ARTERY DISEASE | BIOSTREAM, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| US-6027710-A | PROTECTS THE ACTIVE INGREDIENT OF RADIOPHARMACEUTICALS AGAINST THE RADIOLYSIS CAUSED BY A REACTION OF THE ACTIVE INGREDIENT WITH WATER RADICALS FORMED BY RADIOLYSIS WITHOUT DECOMPOSING THE REACTIVE ACTIVE INGREDIENT (REDUCIBLE) | NIHON MEDI-PHYSISCS CO., LTD. (JP) | 2000-02-22 | — | — | US | disclosed |
| EP-0832654-A2 | Radiation-protecting agent | NIHON MEDI-PHYSICS Co., Ltd. (JP) | 1998-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052129-A1 | METHOD FOR MONITORING BLOOD FLOW AND METABOLIC UPTAKE IN TISSUE WITH RADIOLABELED ALKANOIC ACID | FABP3, FABP1, SLC27A2 | S1PR2 190/4885S1PR1 247/4885S1PR3 156/4885 |
| US-20080214851-A1 | Synthesis of labeled fatty acid analogs for use in tomography | FFAR4, FFAR3, FFAR2 | S1PR2 310/4885S1PR1 383/4885S1PR3 238/4885 |
| US-20080214853-A1 | Labeled cycloalkylidene-containing fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart or tumor | FABP3, FFAR2, FFAR1 | S1PR2 186/4885S1PR1 287/4885S1PR3 195/4885 |
| US-20080213173-A1 | Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor; endo-vinylic variants of cycloalkyl-substituted heptadecanoic acid for example | FABP3, FABP1, FFAR2 | S1PR2 250/4885S1PR1 351/4885S1PR3 270/4885 |
| US-20080213178-A1 | Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate | FFAR3, FFAR2, FFAR1 | S1PR2 97/4885S1PR1 123/4885S1PR3 67/4885 |
| US-20040253177-A1 | Fatty acid derivatives; tissue-targeted therapy; tomography; cardiovascular disorders; liver disorders; kits | FABP1, FABP3, FFAR2 | S1PR2 305/4885S1PR1 391/4885S1PR3 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.